Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration

This study aimed to determine the incidence of poor response to intravitreal (IV) anti-VEGF treatment in neovascular age-related macular degeneration (nvAMD) and to define subgroups of poor responders. A total of 235 treatment-naive eyes of 202 patients completed this prospective study. Patients you...

Full description

Saved in:
Bibliographic Details
Published in:Turk oftalmoloji gazetesi 2020-10, Vol.50 (5), p.275-282
Main Authors: Barış, Mine Esen, Menteş, Jale, Afrashi, Filiz, Nalçaçı, Serhad, Akkın, Cezmi
Format: Article
Language:English
Subjects:
anti-vascular endothelial growth factor
Care and treatment
Macular degeneration
Medical research
neovascular age-related macular degeneration
Neovascularization
Original
Physiological aspects
Ranibizumab
Tıp
treatment response
Vascular endothelial growth factor
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to determine the incidence of poor response to intravitreal (IV) anti-VEGF treatment in neovascular age-related macular degeneration (nvAMD) and to define subgroups of poor responders. A total of 235 treatment-naive eyes of 202 patients completed this prospective study. Patients younger than 50 years of age and those with a contraindication for anti-VEGF therapy were excluded. All eyes were treated with IV ranibizumab. Poor response was defined as recurrence, persistence, or worsening despite treatment. Poor responders were classified into subgroups based on progression patterns. Of the 235 eyes, 78 (33.2%) showed poor response. Pigment epithelial detachment (PED) and occult choroidal neovascularization (CNV) were more common among poor responders (p
ISSN:1300-0659
2149-8695
2149-8709
2147-2661
DOI:10.4274/tjo.galenos.2020.38488